Clinical diagnostics firm Beckman Coulter and medtech company Scopio Labs have entered into a partnership to accelerate the adoption of Scopio’s next-generation peripheral blood smear platforms.

Scopio’s new technology intends to eliminate the use of manual microscopy by using full-field imaging and artificial intelligence (AI)-powered decision support system.

The Scopio systems streamline lab operations and enhance workflow in a distributed network with easy-to-use remote viewing.

The technology also removes the need to ship slides between two locations as it yields high-quality full-field pictures that can be transmitted in real-time across a secure hospital network.

The peripheral blood smear review is a diagnostic tool that gives information about a range of problems, including anaemia, infections, blood-related malignancies, and many other fatal illnesses.

Currently, the majority of these tests are carried out manually but Scopio’s Full-Field Peripheral Blood Smear morphology solution removes the need for manual microscopic analysis.

Scopio Lab’s X100HT records big scan regions at 100X magnification and can hold 30 slides and process up to 40 samples per hour to match the high throughput demands of big hospitals and labs.

Hospital and lab networks may now operate seamlessly across many locations of various sizes with workload balancing, remote consultations and resolving staff shortages, said Beckman Coulter.

Scopio Labs CEO and cofounder Itai Hayut said: “As 70% of all medical decisions depend on laboratory test results, it’s crucial that diagnostic excellence and innovation are placed at the forefront of healthcare.

“It is an honour to partner with Beckman Coulter, the pioneers of automated haematology testing and a known industry innovator, to accelerate the digital transformation of haematology laboratories worldwide.

“By introducing digitalisation to Peripheral Blood Smear review at scale, Scopio completes a crucial piece of the puzzle.

“This partnership is a vote of confidence in our Full-Field cell morphology imaging and AI-powered analysis platform as the market’s new standard – we’re moving away from snapshots of individual cells and into end-to-end digitalisation.”